Gefitinib in non-small-cell lung cancer-An old lesson new re-visited

Translational Lung Cancer Research

Volumn 2, Issue 6, 2013, Pages 435-438

  Dempke, Wolfram C M ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Medical Oncology Department   (Germany)

Author keywords

Editorial; Gefitinib; Maintenance therapy; Non small cell lung cancer (NSCLC)

Indexed keywords

ERLOTINIB; GEFITINIB; PEMETREXED; PLACEBO;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MAINTENANCE CHEMOTHERAPY; MEDIAN SURVIVAL TIME; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL;

EID: 84929675940     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2013.10.01     Document Type: Article

References (18)

1. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008;13 Suppl 1:5-13.
2. Shepherd FA. Second-line chemotherapy for non-small cell lung cancer. Expert Rev Anticancer Ther 2003;3:435-42.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer. N Engl J Med 2002;346:92-8.
4. Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010;67:257-74.
5. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013;105:595-605.
6. Chen X, Liu Y, Røe OD, et al. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage nonsmall cell lung cancer: a systematic review. PLoS One 2013;8:e59314.
7. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-40.
8. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
9. Xu JM, Han Y, Li YM, et al. Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced nonsmall-cell lung cancer. BMC Cancer 2006;6:288.
10. Mencoboni M, Bergaglio M, Serra M, et al. Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer. Anticancer Res 2007;27:4425-9.
11. Pallis AG, Christofillakis Ch, Tselepatiotis E, et al. Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial. Lung Cancer 2007;55:101-7.
12. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-6.
13. Wang MZ, Zhong W, Zhang L, et al. Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2008;30:221-4.
14. Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010;28:753-60.
15. Gaafar RM, Surmont VF, Scagliotti GV, et al. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer 2011;47:2331-40.
16. Ahn MJ, Yang JC, Liang J, et al. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer 2012;77:346-52.
17. Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012;13:466-75.
18. Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-smallcell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-46.